NATALIE MOUNT, PHD
Chief Executive Officer
Natalie is an experienced leader and innovator with a 25 year track record in drug discovery and development roles. Natalie was part of the founding management team at GammaDelta Therapeutics where she served as Chief Scientific Officer from its establishment until 2019. Previously she was part of the founding management team at the Cell and Gene Therapy Catapult as Chief Clinical Officer. Her experience also includes 16 years at Pfizer Research and Development working on different modalities across a range of therapeutic areas. Natalie has also held Independent Director positions on the Boards of biotech companies, including GenSight Biologics and Rinri Therapeutics.
Natalie holds a first class degree in Natural Sciences from University of Cambridge and a PhD from University College, London.
MIHRIBAN TUNA, PHD
Chief Scientific Officer
Mihriban has over 15 years’ experience in biologics drug discovery and development across biotech and pharma. She joined Adaptate from F-star where she was Senior Vice President of Drug Discovery, overseeing all internal and collaborative bispecific antibody programmes from concept through to candidate selection. Previously she held key scientific roles within antibody generation and technology development at Domantis and later in Biopharm R&D at GSK.
She holds a PhD in Biochemistry from the University of Sussex and is currently studying for an executive MBA at the Judge Business School at the University of Cambridge.
MARK UDEN, PHD
Vice President, Pharmaceutical Sciences
Mark has over 20 years’ experience in all areas of early-stage drug development, most recently as Vice President of GammaDelta Therapeutics. Prior to this, he spent 17 years at GSK where, as Senior Director, Biopharm Development, he led a large Department accountable for all early-stage GSK portfolio deliverables ranging from lead molecule de-risking and process development through to phase I/II CMC technology transfer. Prior to GSK, Mark started his career at Oxford Biomedica where he helped co-invent key CMC platform technologies still employed in commercial cell therapy products to this day.
Mark holds a PhD from Imperial College, London.
OXANA POLYAKOVA, PHD
Head of Discovery
Over her 20 year career to date, Oxana has worked as an expert in protein sciences in target discovery through to candidate selection in both pharma and biotech settings, with significant experience discovering biologics for Oncology indications. Oxana was a founding scientist for our antibody discovery work whilst at GammaDelta Therapeutics before moving to her current role at Adaptate.
Oxana holds a PhD from Moscow State University.
Head of Business Operations
Craig’s 15-year career has provided him with broad experience in the areas of business development, finance, operations and market access, spanning nearly all segments of the life science industry. His entrepreneurial drive has led him into numerous start-ups, including as an early employee of NanoString Technologies and as the first employee of the pioneering UK genomics company, Congenica.
Craig holds an MBA from the University of Cambridge, Judge Business School.